WO2012105486A1 - 1日1回隔日投与を特徴とするテガフール含有組成物 - Google Patents
1日1回隔日投与を特徴とするテガフール含有組成物 Download PDFInfo
- Publication number
- WO2012105486A1 WO2012105486A1 PCT/JP2012/051970 JP2012051970W WO2012105486A1 WO 2012105486 A1 WO2012105486 A1 WO 2012105486A1 JP 2012051970 W JP2012051970 W JP 2012051970W WO 2012105486 A1 WO2012105486 A1 WO 2012105486A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dose
- tegafur
- day
- gimeracil
- administered
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to an antitumor agent, and more specifically, an antitumor agent, cancer comprising a combination of tegafur, gimeracil, and oteracil potassium once a day and repeatedly every four days a week
- the present invention relates to the treatment method and use.
- Tegafur, gimeracil and oteracil potassium compounding agent is a combination of terafur, which is a prodrug of fluorouracil (5-FU), gimeracil, which is a decomposition inhibitor of 5-FU, and oteracil potassium, which is a phosphorylation inhibitor. It is an antitumor agent characterized by reducing gastrointestinal toxicity while enhancing its antitumor effect, and is widely used in clinical settings as a cancer chemotherapeutic agent that can be administered orally (Patent Document 1).
- Tegafur tegafur, gimeracil and oteracil potassium combination agents are included in the content of Tegafur: Gimeracil: Oteracil potassium 1: 0.4: 1 "TS-1 combination capsule” and "TS-1 combination granule"
- Gimeracil Oteracil potassium 1: 0.4: 1 "TS-1 combination capsule” and "TS-1 combination granule”
- the dosage and dosage are usually determined for adults as the standard dose, which is the initial dose (one dose) matched to the body surface area, and is orally administered twice daily for 28 days after breakfast and dinner.
- the package insert describes how to administer the drug after 14 days of withdrawal, repeating this as a course.
- the reference amount is determined according to the body surface area.
- the amount of tegafur is 40 mg / dose, 1.25 to 1.5 m 2 is 50 mg / dose, and 1.5 m 2 or more is 60 mg / dose. It is supposed to be times. These dosages can be appropriately increased or decreased depending on the patient's condition.
- Increased dosage is when clinical values judged abnormal due to the administration of this drug (blood test, liver / kidney function test) and gastrointestinal symptoms do not occur, and there is no problem with safety, and it can be increased From the initial reference amount to one step, the dose is 50 mg, 60 mg, and 75 mg / dose, respectively, depending on the body surface area.
- Non-Patent Document 1 As one of the therapeutic methods for solving the essential problem of reducing the patient's bodily discomfort, recently, a method of twice daily administration of TS-1 has been proposed and reported to reduce side effects (for example, Non-Patent Document 1). ⁇ 3). On the other hand, a method of once a day and repeated administration every other day for 3 days in a week has been reported, but it is described that the incidence of adverse events was high and the response rate was low. (Non-Patent Document 4).
- the present invention provides a combination of tegafur, gimeracil and oteracil potassium, which has a higher therapeutic effect by enabling long-term continuous treatment due to low incidence and severity of side effects such as hematological and non-hematological toxicity
- the purpose is to provide new usage of.
- the present inventor conducted research on the method of using a combination drug of tegafur, gimeracil and oteracil potassium.
- the amount of tegafur was once a day for cancer patients when the patient's body surface area was less than 1.25 m 2.
- 80 mg / dose 100 mg / dose for 1.25 to 1.5 m 2 , 120 mg / dose for 1.5 m 2 or more, or more on 4 day intervals in a week
- long-term continuation is possible by significantly reducing the incidence and severity of side effects, resulting in high anti-tumor effects, which can prolong patient survival and improve quality of life (QOL). It was found that this is an effective way to contribute.
- the present invention relates to the following inventions 1) to 12).
- An anti-tumor agent comprising a 1) tegafur gimeracil-oteracil potassium formulation, as tegafur amount, if surface area of the patient to be administered is less than 1.25 m 2 is 80mg / dose, 1.25 ⁇ 1.5 m 2 100 mg / dose, 1.5 mg 2 or more, 120 mg / dose or more, once a day, 4 days a week, 4 days apart, Antitumor agent.
- An anti-tumor agent comprising a 2) tegafur gimeracil-oteracil potassium formulation, as tegafur amount, if surface area of the patient to be administered is less than 1.25 m 2 is 100mg / dose, 1.25 ⁇ 1.5 m 2 120 mg / dose, 1.5 mg 2 or more, 150 mg / dose, or more, once a day, every 4 days in a week Antitumor agent.
- Anti-tumor agent containing tegafur, gimeracil, and oteracil potassium combination, and the maximum blood concentration of 5-FU in patients receiving tegafur, gimeracil, and oteracil potassium combination is 180 to 450 ng / ml
- Anti-tumor agent containing tegafur, gimeracil and oteracil potassium combination drug, and the maximum blood concentration of 5-FU of patients who received tegafur, gimeracil and oteracil potassium combination drug is within 4 hours from administration
- tegafur gimeracil-oteracil potassium formulation as tegafur amount is 80mg / dose when the patient's body surface area administered is less than 1.25 m 2, if it is 1.25 ⁇ 1.5 m 2 100mg /
- a method of treating cancer comprising administering 120 mg / dose once or more when the dose is 1.5 m 2 or more, once a day for 4 days in a week.
- tegafur amount is 100mg / dose when the patient's body surface area administered is less than 1.25 m 2, if it is 1.25 ⁇ 1.5 m 2 120mg /
- a method for treating cancer comprising administering 150 mg / dose once or more when the dose is 1.5 m 2 or more, once a day for 4 days in a week.
- a combination of tegafur, gimeracil, and oteracil potassium for treating cancer wherein the combination is in the amount of tegafur, 80 mg / dose when the body surface area of the patient to be administered is less than 1.25 m 2 , is 100mg / dose in the case of 1.25 ⁇ 1.5 m 2, the 120 mg / dose when it is 1.5 m 2 or more, or more, once a day, 4 days every other day of the week, is repeatedly administered
- a combination of tegafur, gimeracil, and oteracil potassium is in the amount of tegafur, 80 mg / dose when the body surface area of the patient to be administered is less than 1.25 m 2 , is 100mg / dose in the case of 1.25 ⁇ 1.5 m 2, the 120 mg / dose when it is 1.5 m 2 or more, or more, once a day, 4 days every other day of the week, is repeatedly administered
- a combination of tegafur, gimeracil, and oteracil potassium for treating cancer wherein the combination is 100 mg / dose when the body surface area of the patient to be administered is less than 1.25 m 2 as the amount of tegafur. is 120 mg / dose in the case of 1.25 ⁇ 1.5 m 2, the 150 mg / dose when it is 1.5 m 2 or more, or more, once a day, 4 days every other day of the week, is repeatedly administered A combination of tegafur, gimeracil, and oteracil potassium.
- the antitumor agent according to the administration method of the present invention is administered every other day 4 times a week.
- the dosage is less than twice a day for 4 weeks plus 2 weeks off.
- the antitumor agent of the present invention has an antitumor effect equivalent to or higher than the conventional one, and the frequency of occurrence of side effects and Seriousness was found to be greatly reduced.
- the daily dose (tegafur amount) is increased to 80 mg ⁇ 100 mg, 100 mg ⁇ 120 mg, 120 mg ⁇ 150 mg, 150 mg ⁇ 180 mg, the total dose for 6 weeks will be slightly higher than the standard dosage. In this case, despite the large dose, the frequency and severity of side effects are greatly reduced, and the antitumor effect is expected to be better than before.
- the antitumor agent of the present invention achieves both a reduction in side effects and an improvement in drug efficacy as long as it is the same daily dose as described in the package insert that combines a 4-week dosing and 2-week resting twice a day can do. Since the antitumor agent of the present invention is greatly reduced in the frequency and severity of side effects, it can be administered for a long period of time in adjuvant chemotherapy (adjuvant chemotherapy) to suppress recurrence. By increasing, more powerful medicinal effects can be expected.
- the antitumor agent of the present invention contains a combination of tegafur, gimeracil and oteracil potassium as active ingredients.
- the combination drug is an active ingredient, unlike the case of a single drug, by changing the administration method, the drug efficacy can be improved and the frequency and frequency of side effects. It is considered that an unpredictable effect of coexistence of seriousness reduction was realized.
- FIG. 1 is a graph showing the survival rate and survival period of mice obtained in Example 1.
- FIG. 2 is a graph showing changes in the body weight of the mouse obtained in Example 1.
- FIG. 3 is a graph showing changes in blood concentration of 5-FU in subject 1 (when tegafur amount 100 mg was administered) obtained in Example 2.
- FIG. 4 is a graph showing changes in blood concentration of 5-FU in subject 2 (when administering tegafur amount 80 mg) obtained in Example 2.
- FIG. 5 is a graph showing changes in blood concentration of 5-FU in subject 2 (when tegafur amount 120 mg was administered) obtained in Example 2.
- FIG. 6 is a graph showing changes in the blood concentration of 5-FU in subject 3 (when tegafur amount 100 mg was administered) obtained in Example 2.
- FIG. 1 is a graph showing the survival rate and survival period of mice obtained in Example 1.
- FIG. 2 is a graph showing changes in the body weight of the mouse obtained in Example 1.
- FIG. 3 is a graph showing changes in blood concentration of 5-FU in subject 1 (when
- FIG. 7 is a graph showing changes in the blood concentration of 5-FU in subject 4 (when tegafur amount 120 mg was administered) obtained in Example 2.
- FIG. 8 is a graph showing changes in blood concentration of 5-FU in subject 5 (when tegafur amount 120 mg was administered) obtained in Example 2.
- FIG. 9 is a graph showing changes in blood concentration of 5-FU in subject 5 (when tegafur amount 150 mg was administered) obtained in Example 2.
- FIG. 10 is a graph showing changes in blood concentration of 5-FU in subject 6 (when tegafur amount 120 mg was administered) obtained in Example 2.
- the currently used tegafur, gimeracil and oteracil potassium combination is orally administered twice daily after breakfast and dinner for 28 days, then withdrawn for 14 days, and repeated administration as a course
- the method is described in the package insert and is the standard usage.
- the standard dose is determined according to the body surface area as a single dose.
- the body surface area is less than 1.25 m 2
- the tegafur amount is 40 mg / dose
- 1.25 to 1.5 m 2 is 50 mg / dose
- 1.5 m 2 or more is 60 mg. / Times.
- These doses can be adjusted according to the patient's condition.
- the stage of increase is 50 mg / dose for the standard dose of 40 mg / dose, 60 mg / dose for 50 mg / dose, and 60 mg / dose.
- Is 75 mg / dose and it is described that it is limited to a single step increase, so the single dose in the standard dosage is limited to 75 mg / dose.
- Non-Patent Document 1 describes a daily administration group and a daily administration group of TS-1 in a basic test. In other words, it was reported that the TS1 every other day administration group had a relative inhibition period of cancer growth and was less toxic than the daily administration group.
- Non-Patent Document 2 describes the clinical results of 266 gastric cancer patients by the method of administration every other day twice a day, and reports that side effects can be reduced without impairing the therapeutic effect.
- Non-Patent Document 3 describes a method of administering a daily dose of TS-1 twice a day, 50 mg at 15:00, and 100 mg at 22:00 for multiple liver metastases after surgery for duodenal papilla cancer. It has been reported that outpatient treatment was possible without side effects.
- Non-patent Document 4 80 mg of TS-1 which is twice the standard dose is once a day, 3 times a week for patients with advanced recurrent gastric cancer. That is, although a method of administration every other day on Monday, Wednesday and Friday is described, it has been reported that the incidence of adverse events was high and the response rate was low.
- Non-Patent Document 4 tegafur, gimeracil, and oteracil potassium combination doses twice or more of the standard dose administered twice a day or more once a day, every 4 days in a week
- the method of repeated administration by day was an administration method that cannot be recalled from the prior art.
- the present inventors have found that the amount of body surface of a patient to be administered is less than 1.25 m 2, which is twice the single dose determined in the package insert as a standard amount per body surface area in terms of tegafur. 80mg / dose as tegafur amount if, 1.25 ⁇ 1.5 m 2 and is the 100mg / dose when, 1.5 m 2 or more at which the 120 mg / dose in the case), or more, once a day, 1 week
- the incidence and severity of side effects are lower than expected, It was found that the administration method has a higher therapeutic effect.
- the antitumor agent of the present invention can achieve both a high antitumor effect and reduction of side effects.
- “Repeatedly administered every 4 days in a week” means that 4 days are selected so that the days on which tegafur, gimeracil, and oteracil potassium are not administered continue in a week. It is meant to be administered weekly every day of the week. Specifically, 4 days in a week means 4 days on Monday, Wednesday, Friday, and Sunday, 4 days on Monday, Tuesday, Thursday, and Saturday, or 4 days on Monday, Wednesday, Friday, and Saturday. It means, but is not limited to these.
- an “antitumor agent” is useful for the treatment of cancer or tumor and / or prevention of recurrence. Accordingly, the present invention provides a therapeutic agent for cancer or tumor and a preventive agent for recurrence.
- prevention of recurrence means prevention of recurrence of cancer or tumor after cancer or tumor tissue has once disappeared or cannot be recognized by surgery, radiation therapy, chemotherapy or the like.
- tegafur amount is 80mg / dose when the patient's body surface area administered is less than 1.25 m 2, if it is 1.25 ⁇ 1.5 m 2 100mg / dose, 1.5 m 120 mg / dose or more if 2 or more, once a day, every 4 days in a week, or if the patient's body surface area administered is less than 1.25 m 2 100 mg / dose, 120 mg / dose for 1.25-1.5 m 2 , 150 mg / dose for 1.5 m 2 or more, once a day, every 4 days in a week Repeated administration.
- the administration period for preventing recurrence is usually about 1 month to 1 year, especially about 3 months to 6 months. By continuing to take the antitumor agent during this period, recurrence of cancer or tumor can be prevented.
- the antitumor agent of the present invention is administered once a day, the dose per administration is larger than that administered twice a day, and the blood concentration of 5-FU as an active ingredient is also increased.
- the maximum blood concentration of 5-FU is about 180 to about 450 ⁇ ng / ml It is considered to be within the range. This blood concentration can increase proportionally with increasing daily dose.
- the daily dose of the antitumor agent of the present invention is exemplified by the following amount as a tegafur equivalent amount according to the patient's body surface area (Table 1).
- the "80mg / dose or more in the case the surface of the patient is less than 1.25 m 2" or "100mg / dose or more in the case the surface of the patient is less than 1.25 m 2"
- a daily dose selected from the above The same applies when the patient's body surface area is 1.25 to 1.5 m 2 , 1.5 m 2 or more.
- the blood concentration of 5-FU reaches its maximum value within 4 hours after administration, for example, around 3 hours. Thereafter, the blood concentration rapidly decreases within 24 hours, and almost disappears 24 hours after administration.
- the blood concentration of 5-FU will be 10 ng / ml or less within 24 hours after administration" means that the 5-FU concentration in blood will almost disappear within 24 hours of administration. This means that the side effects derived from it hardly occur.
- composition The antitumor agent of the present invention can be administered as a pharmaceutical composition.
- pharmaceutical composition may be referred to as “composition”.
- the form is not particularly limited as long as it is a composition for oral administration containing tegafur, gimeracil and oteracil potassium.
- examples of the composition include tablets, coated tablets, granules, fine granules, powders, capsules, pills, emulsions, suspensions, liquids and the like.
- lactose sucrose, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, silicic acid and other excipients, water, ethanol, propanol, simple syrup, glucose solution , Starch solution, gelatin solution, binders such as carboxymethylcellulose, shellac, methylcellulose, potassium phosphate, polyvinylpyrrolidone, dry starch, sodium alginate, agar powder, laminaran powder, sodium bicarbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid ester Disintegrators such as sodium lauryl sulfate, stearic acid monoglyceride, starch, lactose, disintegrators such as sucrose, stearic acid, cocoa butter, hydrogenated oil, quaternary ammonium base, sodium lauryl sulfate, etc.
- binders such as carboxymethylcellulose, shellac, methylcellulose, potassium phosphate, polyvinylpyrrolidone
- Absorption accelerators such as glycerin and starch, adsorbents such as starch, lactose, kaolin, bentonite and colloidal silicic acid, lubricants such as purified talc, stearate, boric acid powder, polyethylene glycol, etc.
- the tablet can be made into a tablet coated with a normal coating as necessary, for example, a sugar-coated tablet, a gelatin-encapsulated tablet, an enteric-coated tablet, a film-coated tablet, a double-coated tablet, a multilayer tablet, or the like.
- excipients such as glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, kaolin, talc, gum arabic powder, tragacanth powder, binders such as gelatin, ethanol, laminaran powder, Disintegrants such as Kanteng powder can be used.
- Capsules are prepared by mixing tegafur, gimeracil and oteracil potassium with the various carriers exemplified above and filling them into hard gelatin capsules, hard capsules and the like.
- each of the above-mentioned preparations may be blended with a coloring agent, a preservative, a fragrance, a flavoring agent, a sweetening agent, and other medicines as necessary.
- gimeracil is usually about 0.1 to 5 mol, preferably about 0.1 to 1.5 mol, and oteracil potassium per mol of tegafur. Is preferably in the range of about 0.1 to 5 mol, preferably about 0.2 to 2 mol, particularly preferably a drug containing tegafur, gimeracil and oteracil potassium in a molar ratio of 1: 0.4: 1 respectively. It is a composition. Moreover, even if it is a formulation containing these three components in one formulation, these three components may be a combination of different dosage forms (for example, tablets and capsules). A preparation containing three components in the preparation is preferred.
- the disease to which the antitumor agent of the present invention is applied is not particularly limited.
- head and neck cancer nasopharyngeal cancer, oropharyngeal cancer, hypopharyngeal cancer, pharyngeal cancer, esophageal cancer, stomach cancer, colorectal cancer, liver Cell cancer, gallbladder / bile duct cancer, pancreatic cancer (pancreatic head cancer, pancreatic body cancer), lung cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, renal cancer, testicular tumor, bone / soft tissue sarcoma, malignant lymphoma, leukemia, uterus
- cervical cancer skin cancer, brain tumor and the like, and particularly preferred are head and neck cancer, lung cancer, stomach cancer, colorectal cancer, pancreatic cancer, breast cancer and biliary tract cancer.
- the cancer patient to whom the antitumor agent of the present invention is administered may be a patient who has never been treated for cancer or who is currently undergoing treatment. It may be a patient.
- the antitumor agent of the present invention may be used in combination with other antitumor agents and radiation therapy.
- the antitumor agents that can be used in combination include doxorubicin, epirubicin, irinotecan hydrochloride, etoposide, docetaxel, paclitaxel, cisplatin, carboplatin Oxaliplatin, krestin, lentinan, picibanil, folinate, levofolinate.
- each formulation When used in combination with another antitumor agent, it may be in a single-form formulation containing the antitumor agent of the present invention, or may be in a separate formulation. In the case of separate formulations, each formulation can be administered with other components at the same time, before administration of one component, or at any later time. It is preferable to administer at the same time.
- the administration means of the composition containing the antitumor agent of the present invention and the administration means of the composition containing the antitumor agent used together may be the same or different (for example, oral administration and injection).
- the antitumor agent of the present invention is usually administered after meals, but if administered once a day, it does not matter when it is administered (after breakfast, after lunch, after dinner).
- Test solution of TS-1 (TS-1, Taiho Pharmaceutical Co., Ltd.) was prepared with 0.5% hydroxypropylmethylcellulose as tegafur amounts of 0.83 mg / mL and 1.44 mg / mL.
- the daily administration group was orally administered daily from day 1 to 140 at a maximum tolerated dose (Maximum Tolerated Dose; MTD) of 8.3 mg / kg / day.
- MTD Maximum Tolerated Dose
- the group administered every other day was orally administered with an MTD of 14.4 mg / kg / day every other day from day 1 to 140.
- survival rate and survival rate [increase in life span; ILS (%)] were calculated by the following formula.
- the survival rate and survival period of each group are shown in FIG. It should be noted that the survival period of mice that survived on day 140 was 140 days.
- ILS (%) [(average survival time of drug administration group) / (average survival time of control group) ⁇ 1] ⁇ 100
- the ILS of the TS-1 daily administration group and the biday administration group were 26.5% and 99.3%, respectively, and the survival period was significantly prolonged by TS-1 administration compared with the Control group (p ⁇ 0.01). Furthermore, the survival group of the every other day administration group significantly prolonged the survival time compared to the daily administration group (p ⁇ 0.05). That is, as shown also in FIG. 1, it was revealed that TS-1 every other day administration showed an excellent antitumor effect.
- BWC (%) [(BW on day n)-(BW on day 0)] / (BW on day 0) x 100
- the single dose of TS-1 in the every other day administration group was 14.4 mg / kg / day, which was higher than the 8.3 mg / kg / day in the daily administration group, While severe weight loss with diarrhea was observed, almost no weight loss was seen in the every other day administration group.
- the treatment method using the antitumor agent of the present invention can be administered in a dose of about 1.7 times the daily administration method as a daily dose, and exhibits an excellent antitumor effect and low toxicity. It became clear. In other words, in clinical practice, it was suggested that it excels in QOL and contributes significantly to the extension of patient survival.
- Example 2 TS-1 capsules (TS-1, Taiho Pharmaceutical Co., Ltd.) are administered once a day for 6 weeks on Monday, Wednesday, Friday, and Sunday every four days of the week. Repeat treatment as one course. The first administration starts on Monday, Wednesday, Friday, or Sunday (regular day), and the day when TS-1 administration is started is designated as Day1.
- the first course take the initial dose (tegafur amount) shown in Table 2 once a day after breakfast.
- the first dose will be changed from the initial dose according to the increased dose level shown in Table 1 after the second course. Increase the amount. Even if the dose is increased, the dose is taken once a day after breakfast, and the administration schedule on Monday, Wednesday, Friday, and Sunday is unchanged.
- Table 3 shows patient information, dosage, administration continuation status, etc. (age and body surface area in the table indicate those at the first administration).
- hematological toxicity decrease in leukocyte count, neutrophil count, hemoglobin count, or platelet count
- TS-1 hematological toxicity
- Example 3 For each subject of Example 2, the blood concentration transition of 5-fluorouracil (5-FU) was predicted. The prediction method was based on the method described in Journal of Pharmacokinetics and Pharmacodynamics, (2003) 30, 257-283, and concentration transition prediction from sample data (sparse sampling data) at several time points by Bayesian estimation method was used.
- Blood levels of tegafur, 5-FU, and gimeracil measured 3 hours, 7 hours, and 24 hours (only in some cases) after taking TS-1, and subject's sex, age, body surface area, and cycle start Serum creatinine concentration of 5-FU was calculated using NONMEM ⁇ ⁇ version VI level 2.0 (GloboMax, ICON Develop. Lution Solutions, Ellicott City, MD, USA) did.
- FIGS. 3 to 10 show changes in blood levels of 5-FU during the first course of subjects 1 to 6. As is apparent from FIGS. 3 to 10, the maximum blood concentration of 5-FU was shown around 3 hours after administration, and the value was 180 to 450 ⁇ ng / ml. Thereafter, 5-FU in the blood decreased rapidly and almost disappeared 24 hours after administration.
Abstract
Description
大量培養したヒト胃癌株NUGC-4をトリプシン処理及び遠心洗浄した後、1×107 cells/mLの密度の細胞浮遊液として調製した。注射筒を用いて、1匹当たり0.5 mLの細胞浮遊液を生後5~6週齢の雄性BALB/cA Jcl-nuマウスの腹腔内に移植した。マウスの体重を測定後、MiSTAT ver.1.72の群分けプログラムを用いて、各群の平均体重が均等になるように各群にマウスを割り付け、この群分け(n=10)を実施した日をday 0とした。
ILS(%)=[(薬剤投与群の平均生存期間)/(Control群の平均生存期間)-1]×100
TS-1連日投与群と隔日投与群のILSは、それぞれ26.5%と99.3%であり、Control群に比較して、TS-1投与によりそれぞれ生存期間を有意に延長した(p<0.01)。さらに隔日投与群は、連日投与群に対しても有意に生存期間を延長した(p<0.05)。すなわち、図1にも示されるように、TS-1隔日投与が優れた抗腫瘍効果を示すことが明らかとなった。
隔日投与群におけるTS-1の1回投与量は14.4 mg/kg/dayであり、連日投与群の8.3 mg/kg/dayに比較して高用量であったにも関わらず、連日投与群は下痢を伴う激しい体重減少が観察された一方、隔日投与群では、体重減少が殆ど見られなかった。
ティーエスワンカプセル(TS-1、大鵬薬品工業株式会社)を1日1回、1週間のうち4日間隔日の月曜、水曜、金曜、及び日曜に、繰り返し6週間投与を行い、この6週を1コースとして治療を繰り返す。初回投与は月曜、水曜、金曜、日曜いずれかの曜日(規定曜日)で開始し、TS-1を投与開始した日をもって、Day1とする。
実施例2のそれぞれの被験者について、5-フルオロウラシル(5-FU)の血中濃度推移予測を行った。予測方法は、Journal of Pharmacokinetics and Pharmacodynamics, (2003) 30, 257-283に記載の方法に準じて、ベイジアン推定法による数時点のサンプルデータ(スパースサンプリングデータ)からの濃度推移予測を用いた。
Claims (12)
- テガフール・ギメラシル・オテラシルカリウム配合剤を含む抗腫瘍剤であって、テガフール量として、投与される患者の体表面積が1.25m2未満である場合には80mg/回、1.25~1.5 m2である場合には100mg/回、1.5m2以上である場合には120mg/回、又はそれ以上を、1日1回、1週間のうち4日間隔日で、繰り返し投与されることを特徴とする抗腫瘍剤。
- テガフール・ギメラシル・オテラシルカリウム配合剤を含む抗腫瘍剤であって、テガフール量として、投与される患者の体表面積が1.25m2未満である場合には100mg/回、1.25~1.5 m2である場合には120mg/回、1.5m2以上である場合には150mg/回、又はそれ以上を、1日1回、1週間のうち4日間隔日で、繰り返し投与されることを特徴とする抗腫瘍剤。
- テガフール・ギメラシル・オテラシルカリウム配合剤を含む抗腫瘍剤であって、テガフール・ギメラシル・オテラシルカリウム配合剤を投与された患者の5-FUの最大血中濃度が180~450 ng/mlを示し、且つ投与から24時間以内に10 ng/ml以下となることを特徴とする、請求項1又は2に記載の抗腫瘍剤。
- テガフール・ギメラシル・オテラシルカリウム配合剤を含む抗腫瘍剤であって、テガフール・ギメラシル・オテラシルカリウム配合剤を投与された患者の5-FUの最大血中濃度が、投与から4時間以内に180~450 ng/mlを示し、且つ投与から24時間以内に10 ng/ml以下となることを特徴とする、請求項1乃至3に記載の抗腫瘍剤。
- テガフール・ギメラシル・オテラシルカリウム配合剤における各有効成分のモル比が、テガフール:ギメラシル:オテラシルカリウム=1:0.4:1である、請求項1乃至4に記載の抗腫瘍剤。
- 前記配合剤が、毎週月曜、水曜、金曜、及び日曜に繰り返し投与されることを特徴とする、請求項1乃至5に記載の抗腫瘍剤。
- テガフール・ギメラシル・オテラシルカリウム配合剤を、テガフール量として、投与される患者の体表面積が1.25m2未満である場合には80mg/回、1.25~1.5 m2である場合には100mg/回、1.5m2以上である場合には120mg/回、又はそれ以上を、1日1回、1週間のうち4日間隔日で、繰り返し投与することを特徴とする、癌の治療方法。
- テガフール・ギメラシル・オテラシルカリウム配合剤を、テガフール量として、投与される患者の体表面積が1.25m2未満である場合には100mg/回、1.25~1.5 m2である場合には120mg/回、1.5m2以上である場合には150mg/回、又はそれ以上を、1日1回、1週間のうち4日間隔日で、繰り返し投与することを特徴とする、癌の治療方法。
- 癌を治療するための医薬製造のためのテガフール・ギメラシル・オテラシルカリウム配合剤の使用であって、前記配合剤はテガフール量として、投与される患者の体表面積が1.25m2未満である場合には80mg/回、1.25~1.5 m2である場合には100mg/回、1.5m2以上である場合には120mg/回、又はそれ以上を、1日1回、1週間のうち4日間隔日で、繰り返し投与されることを特徴とする、使用。
- 癌を治療するための医薬製造のためのテガフール・ギメラシル・オテラシルカリウム配合剤の使用であって、前記配合剤はテガフール量として、投与される患者の体表面積が1.25m2未満である場合には100mg/回、1.25~1.5 m2である場合には120mg/回、1.5m2以上である場合には150mg/回、又はそれ以上を、1日1回、1週間のうち4日間隔日で、繰り返し投与されることを特徴とする、使用。
- 癌を治療するためのテガフール・ギメラシル・オテラシルカリウム配合剤であって、前記配合剤はテガフール量として、投与される患者の体表面積が1.25m2未満である場合には80mg/回、1.25~1.5 m2である場合には100mg/回、1.5m2以上である場合には120mg/回、又はそれ以上を、1日1回、1週間のうち4日間隔日で、繰り返し投与されることを特徴とする、テガフール・ギメラシル・オテラシルカリウム配合剤。
- 癌を治療するためのテガフール・ギメラシル・オテラシルカリウム配合剤であって、前記配合剤はテガフール量として、投与される患者の体表面積が1.25m2未満である場合には100mg/回、1.25~1.5 m2である場合には120mg/回、1.5m2以上である場合には150mg/回、又はそれ以上を、1日1回、1週間のうち4日間隔日で、繰り返し投与されることを特徴とする、テガフール・ギメラシル・オテラシルカリウム配合剤。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12741901.8A EP2671590A4 (en) | 2011-01-31 | 2012-01-30 | COMPOSITION CONTAINING TEGAFUR FOR SINGLE DAILY DOSAGE OR DAY ON TWO |
US13/982,354 US20140038966A1 (en) | 2011-01-31 | 2012-01-30 | Tegafur-containing composition for single daily and alternate-day dosing |
JP2012555857A JPWO2012105486A1 (ja) | 2011-01-31 | 2012-01-30 | 1日1回隔日投与を特徴とするテガフール含有組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011018616 | 2011-01-31 | ||
JP2011-018616 | 2011-01-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012105486A1 true WO2012105486A1 (ja) | 2012-08-09 |
Family
ID=46602700
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/051970 WO2012105486A1 (ja) | 2011-01-31 | 2012-01-30 | 1日1回隔日投与を特徴とするテガフール含有組成物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20140038966A1 (ja) |
EP (1) | EP2671590A4 (ja) |
JP (1) | JPWO2012105486A1 (ja) |
TW (1) | TW201236686A (ja) |
WO (1) | WO2012105486A1 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2614164B2 (ja) | 1991-05-27 | 1997-05-28 | 大鵬薬品工業株式会社 | 抗腫瘍効果増強のための及び腫瘍治療のための組成物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4994618B2 (ja) * | 2005-08-11 | 2012-08-08 | 学校法人北里研究所 | Ts−1/カンプトテシン類による化学放射線療法 |
WO2010131769A1 (en) * | 2009-05-13 | 2010-11-18 | Taiho Pharmaceutical Co., Ltd. | Treatment of diffuse-type gastric cancers using s-1 and cisplatin |
-
2012
- 2012-01-30 US US13/982,354 patent/US20140038966A1/en not_active Abandoned
- 2012-01-30 WO PCT/JP2012/051970 patent/WO2012105486A1/ja active Application Filing
- 2012-01-30 EP EP12741901.8A patent/EP2671590A4/en not_active Withdrawn
- 2012-01-30 JP JP2012555857A patent/JPWO2012105486A1/ja not_active Withdrawn
- 2012-01-31 TW TW101103047A patent/TW201236686A/zh unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2614164B2 (ja) | 1991-05-27 | 1997-05-28 | 大鵬薬品工業株式会社 | 抗腫瘍効果増強のための及び腫瘍治療のための組成物 |
Non-Patent Citations (10)
Title |
---|
"TS-1 Tenpu Bunsho", 2010 NEN 7 GATSU, XP008170056, Retrieved from the Internet <URL:http://www.info.pmda.go.jp/downfiles/ph/PDF/400107_4229101D1025_1_03.pdf> [retrieved on 20120221] * |
"UMIN CTR Rinsho Shiken Toroku Joho no Etsuran", UMIN CTR RINSHO SHIKEN TOROKU JOHO NO ETSURAN, 1 December 2010 (2010-12-01), XP008170054, Retrieved from the Internet <URL:https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000005467&language=J> [retrieved on 20120221] * |
INT J CLIN ONCOL, vol. 13, 2008, pages 515 - 520 |
INT J CLIN ONCOL, vol. 15, 2010, pages 166 - 171 |
JAPANESE FOUNDATION FOR MULTIDISCIPLINARY TREATMENT OF CANCER, RINSHO SHIKEN JFMC43-1003, 21 February 2012 (2012-02-21), XP055119878, Retrieved from the Internet <URL:http://www.jfmc.or.jp/product/prod04/report/JFMC43_1003.pdf> [retrieved on 20120221] * |
NIHON GAN CHIRYO GAKKAISHI, THE JOURNAL OF JAPAN SOCIETY OF CLINICAL ONCOLOGY, vol. 38, no. 2, 2003, pages 518 |
See also references of EP2671590A4 * |
TETSUHIKO SHIROSAKA: "S-1(TS-1) no Kaihatsu Keii to Saranaru Kaizen o Mezashite", JAPAN GASTROENTEROLOGICAL ENDOSCOPY SOCIETY ZASSHI, vol. 52, no. 2, 10 September 2010 (2010-09-10), pages 2180, XP008170057 * |
THE JAPANESE JOURNAL OF GASTROENTEROLOGICAL SURGERY, vol. 39, no. 4, 2006, pages 486 |
THE JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, vol. 30, 2003, pages 257 - 283 |
Also Published As
Publication number | Publication date |
---|---|
US20140038966A1 (en) | 2014-02-06 |
TW201236686A (en) | 2012-09-16 |
EP2671590A4 (en) | 2014-09-03 |
EP2671590A1 (en) | 2013-12-11 |
JPWO2012105486A1 (ja) | 2014-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5576591B2 (ja) | α,α,α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 | |
JP2005008534A (ja) | 抗癌剤及び癌の治療方法 | |
TW201907916A (zh) | 基於癌細胞之代謝特異性之新穎抗惡性腫瘤劑 | |
US20240148730A1 (en) | Method for treating cancer patients with severe renal impairment | |
CN111629718A (zh) | 对癌症患者的治疗有用的尿碱剂 | |
JP6973456B2 (ja) | 癌化学療法時の副作用軽減剤 | |
TWI598095B (zh) | 治療或緩解高齡或末期癌症患者用之醫藥組合物 | |
WO2012105486A1 (ja) | 1日1回隔日投与を特徴とするテガフール含有組成物 | |
Sugimachi et al. | A phase II trial of a new 5-fluorouracil derivative, BOF-A2 (Emitefur), for patients with advanced gastric cancer | |
EP2826482A1 (en) | Novel antitumor agent comprising combination of three agents | |
EP3127544B1 (en) | Anti-tumor drug containing anti-tumor platinum complex, and anti-tumor effect enhancer | |
JP2004533434A (ja) | テガフール、ウラシル、フォリン酸およびシクロホスファミドの投与による腫瘍の治療方法 | |
WO2022014025A1 (ja) | 血液がんの新規治療法及び新規治療剤 | |
US11246847B2 (en) | Anticancer drug effect enhancer | |
CN112770759A (zh) | 用于治疗伴脑转移的晚期非小细胞肺癌患者的组合药物 | |
EP4284378A1 (en) | Ptentreating cancer in patient with pten inactivating mutation | |
JP2003300888A (ja) | 抗腫瘍効果増強剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12741901 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2012555857 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012741901 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13982354 Country of ref document: US |